The induction of a humoral immune response is complex. It involves initial activation of resting B cells, subsequent proliferation of the activated precursors, and differentiation of the activated cells into mature immunoglobulin-secreting cells. The process of differentiation has been studied by using Staphylococcus aureus Cowan 1 to bind to the antigen receptor because it can induce B-cell DNA synthesis in a T-cell-independent manner (16, 48) . One of the many changes in gene expression during B-cell activation is an increase in the expression of bcl-2 at the mRNA level (22, 45) .
Engagement of the B-cell antigen receptor leads to differing outcomes depending on the stage of development of the B cell. Apoptosis plays a key role in this process. In the bone marrow, self-reactive immature surface IgM ϩ IgD Ϫ B cells are eliminated by apoptosis; this process leads to induction of tolerance. At the pro-B-cell stage, as immunoglobulin (Ig) gene rearrangement is occurring, the vast majority of cells die by apoptosis. Binding of antigen to the antigen receptor in immature B cells leads to death by apoptosis (13, 26) . In cell line models, this is associated with a decrease in the level of bcl-2 mRNA (14) . Anti-CD40 antibodies protect against apoptosis and result in an increase in the expression of bcl-2 (52) .
Apoptosis plays a role in the development of mature lymphocytes. In the germinal centers, widespread apoptosis is observed. Engagement of surface Ig leads to rescue from apoptosis. Increased expression of bcl-2 is observed when germinal-center cells are prevented from undergoing apoptosis (33, 35) . Binding of antigen to the B-cell receptor in resting B cells leads to proliferation. Binding of antigen to the B-cell receptor on either germinal-center cells or resting B cells leads to a similar pattern of second-messenger induction, including activation of Src and Src-related protein kinases (4, 60) , phosphorylation on tyrosine residues of a number of substrates (3, 6, 20, 31) , engagement of G proteins (19, 25, 39) , increased inositol 1,4,5-triphosphate levels, increased intracellular calcium levels, and activation of protein kinase C (PKC) (5, 9) . Activation of PKC leads to activation of NF-B and AP-1, as well as other transcription factors (10, 34, 54 ). Burkitt's lymphoma cells undergo apoptosis after ligation of surface IgM or treatment with a calcium ionophore (2, 7, 18, 23, 28, 53) . Group I Burkitt's lymphoma cells display a surface phenotype characteristic of germinal-center cells, and they have been used as a model for germinal-center B cells (28) . Activation of PKC by phorbol esters reduces apoptosis induced by calcium ionophores or surface IgM ligation (53) . Apoptosis can also be triggered by inhibitors of PKC. High-level expression of Bcl-2 protects Burkitt's lymphoma cells from apoptosis induced by ionomycin or surface IgM cross-linking (28, 42) . Treatment of Burkitt's lymphoma cells with phorbol esters causes an up-regulation of bcl-2 mRNA and protein (18) . Tumor necrosis factor alpha protects Burkitt's lymphoma cell lines from apoptosis induced by ionomycin by up-regulation of bcl-2 by a mechanism that is dependent on PKC (18) .
The major transcriptional promoter for bcl-2, P1, is located 1,386 to 1,423 bp upstream of the translation start site (50) . This is a TATA-less, GC-rich promoter that displays multiple transcription state sites. A minor promoter, P2, which is used in some cell types, is located 1.3 kb downstream from the first one (50) . Little information is available concerning the transcriptional control of the bcl-2 gene. A negative regulatory element upstream of the P2 promoter has been described previously (61) . The proteins that bind to this element have not been identified, although p53 was shown to mediate downregulation of bcl-2 either directly or indirectly through a 195-bp fragment of this region (37) . We have previously described three 1-binding sites which are negative regulators of bcl-2 expression in pre-B cells (8) . Normal pre-B cells express very little bcl-2, and extensive cell death by apoptosis occurs at this developmental stage. Bcl-2 protein levels are increased in mature B cells. We have found that the three 1 sites are not functional in mature B cells (8) . In the present study, we characterize the regulatory regions, including a cyclic AMP (cAMP)-responsive element (CRE), that are responsible for the positive regulation of bcl-2 expression in both pre-B cells and mature B cells.
Elevation of intracellular cAMP levels can result in either stimulation or repression of specific gene expression; most of these genes contain one or more CREs. The consensus CRE sequence is GTGACGTCA. cAMP binds to the regulatory subunit of PKA and releases the active catalytic subunit. This subunit phosphorylates the transactivation domain of CREbinding protein (CREB), which then induces the expression of genes containing CREs. Mutation of the phosphoacceptor site (Ser-133) results in a dominant negative form of CREB (1, 51) . A number of CREBs, including CREB, CRE modulator, and several activating transcription factors (ATFs), have been described. The CREBs are basic leucine zipper transcription factors and are active as either homo-or heterodimers. Some of the ATFs heterodimerize with members of the Jun/Fos family of proteins (for reviews, see references 30, 32, and 36).
We have elucidated the mechanism of increased bcl-2 expression during B-cell activation in mature B cells and during rescue from calcium-dependent apoptosis of immature B cells. We have found that a CRE mediates the increase in bcl-2 expression following surface Ig cross-linking in mature B cells or treatment with phorbol esters in both mature and immature B cells. Furthermore, we present evidence that PKC is responsible for the activation of CREB by phosphorylation. Optimal bcl-2 activation occurs when the phosphorylated CREB interacts with an upstream regulatory region, suggesting that phosphorylation changes the interaction of CREB with neighboring promoter elements.
MATERIALS AND METHODS
Plasmid constructs. A DNA fragment from BamHI (Ϫ3934) to SacI (Ϫ1287) of the human bcl-2 gene (a generous gift from Michael Cleary, Stanford University) was inserted into a luciferase reporter vector with PstI linkers. Numbering of the bcl-2 sequence is relative to the translation start site. Progressive 5Ј truncations of the bcl-2 sequence by restriction digestion gave rise to constructs spanning the sequence from SacI (Ϫ1287) to XhoI (Ϫ2857), AvrII (Ϫ2337), NotI (Ϫ1794), SacII (Ϫ1743), SacII (Ϫ1693), SacII (Ϫ1640), BsrFI (Ϫ1526), and ApaI (Ϫ1337). Additional 5Ј truncations were generated by PCR subfragment cloning to form constructs spanning the sequence from SacI (Ϫ1287) to introduced BamHI sites at Ϫ1473 and Ϫ1413 (see Fig. 1 ).
To study the activity observed between SacII (Ϫ1640) and BsrFI (Ϫ1526) in more detail, subfragments of this area generated by PCR cloning or oligonucleotide synthesis were inserted into a polylinker at the BsrFI site in the Ϫ1526-bcl-2 plasmid constructed as described above. Progressive 5Ј-subfragment truncations spanning from Ϫ1526 to Ϫ1640, to Ϫ1611, to Ϫ1578, to Ϫ1564, and to Ϫ1552 were inserted in this polylinker. Interposition of the polylinker between contiguous bcl-2 sequences at site Ϫ1526 did not alter promoter activity when compared with analogous controls without polylinker (data not shown). A plasmid containing the wild-type upstream regulatory element (WtURE) was constructed in the same manner by inserting the PCR-cloned sequence Ϫ1640 to Ϫ1544 in the polylinker 5Ј of the Ϫ1526-bcl-2 plasmid. A plasmid containing the wild-type downstream regulatory element (WtDRE), including the endogenous bcl-2 CRE site, was constructed by inserting the synthesized oligonucleotide sequence Ϫ1552 through Ϫ1535 in the polylinker 5Ј of the Ϫ1526-bcl-2 plasmid. Plasmids with mutations in and near the CRE site were constructed similarly with the sequences shown in Table 1 . The following base pairs were mutated (with plasmid name in parentheses): Ϫ1552 and Ϫ1548 (mC1,4); Ϫ1551 through Ϫ1549 (mC2-3); Ϫ1547 and Ϫ1545 (mC6,8); Ϫ1541 and Ϫ1540 (mC12,13); Ϫ1540 and Ϫ1539 (mC13,14); and Ϫ1540 through Ϫ1536 (mC13-17). A construct (MutCRE) with the CRE site changed from GTGACGTTA to GTGAA TTTA was prepared from the Ϫ1640 construct with the Quikchange site-directed mutagenesis kit (Stratagene). A construct containing two CRE sites was prepared by inserting CRE oligonucleotides with SalI and XhoI ends into the SalI site of the pGL2 promoter, a luciferase reporter gene linked to the simian virus 40 promoter (Promega). A similar construct containing two copies of the Ig heavy-chain enhancer 1 site has been described previously (8) . All plasmid sequences were confirmed by the dideoxynucleotide method (Sequenase; U.S. Biochemical). The CRE-dependent plasmid (BglII CAT) and Rous sarcoma virus (RSV) CREB and RSV CREB M1 were obtained from Marc Montminy, Salk Institute. The BglII CAT construct contains the somatostatin gene promoter from Ϫ71 to ϩ53 linked to the chloramphenicol acetyltransferase (CAT) reporter gene (40) . RSV CREB expresses full-length CREB from the RSV promoter, and RSV CREB M1 expresses full-length CREB with serine 133 changed to alanine (21) .
Cell lines and transient-transfection assays. Nall-1, a human pre-B-cell line, and DHL-9, a human mature B-cell line, were cultured in RPMI medium supplemented with 10% fetal calf serum, 100 U of penicillin per ml, 100 g of streptomycin per ml, and 2 mM L-glutamine. Neither cell line has a translocation involving the bcl-2 locus. The Epstein-Barr virus-negative Burkitt's lymphoma cell line, Ramos, was grown in RPMI medium supplemented with 10% fetal calf serum. BAL-17 cells, a murine B-lymphoma cell line, were kindly provided by William Paul and Richard Asofsky, National Institutes of Health, Bethesda, Md. BAL-17 cells are a model for mature B cells and were cultured in RPMI medium supplemented with 5% fetal calf serum, 100 U of penicillin per ml, 100 g of streptomycin per ml, 2 mM L-glutamine, 10% NCTC 109, and 0.1% ␤-mercaptoethanol. Cell viability was determined by trypan blue exclusion.
DNA transfections were performed with cells in the log phase (5 ϫ 10 5 to 6 ϫ 10 5 cells per ml). The cells were washed with RPMI medium and resuspended at 3 ϫ 10 7 cells per ml in RPMI medium containing 26 g of DEAE-dextran per ml (17) . A total of 10 to 20 g of plasmid DNA was added, and electroporation was performed with a Bio-Rad gene pulser at 960 F and 350 mV for DHL-9, 320 mV for Ramos, 300 mV for Nall-1, or 400 mV for BAL-17 cells. Transfected cells were cultured in 25 ml of supplemented RPMI medium for 48 h. Reporter gene activity was determined by the luciferase assay system (Promega), and luminescence was quantitated with an LKB 1251 luminometer. Variation in transfection efficiency was controlled for by cotransfection with 5 g of an RSV long terminal repeat-␤-galactosidase or a simian virus 40 promoter-␤-galactosidase plasmid. Each assay was performed at least three times in duplicate with at least two different plasmid preparations. The normalized mean values with standard deviations were plotted or reported in tabular form. Phorbol 12-myristate 13-acetate (PMA), forskolin, ionomycin, or goat anti-mouse IgM was added at the concentrations indicated in Fig. 7C, 8A , and 9C. Cells were harvested after 18 h ( Fig. 7C and 8A ) or 6 h (Fig. 9C) .
EMSA. The oligonucleotides used as probes for the electrophoretic mobility shift assay (EMSA) of the CRE region are shown in Table 1 (see below). The sequence of the CRE consensus oligonucleotide was GAACCGTGTGACGTC ACGCG. The oligonucleotides were synthesized with 5Ј overhangs and end labeled with [␣-32 P]dCTP and Klenow polymerase. Binding conditions were as follows: 12 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES; pH 7.9), 4 mM Tris (pH 7.5), 100 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, 5% glycerol, 3 g of poly(dI-dC), 1 ng (10 4 cpm) of end-labeled oligonucleotide probe, and 10 g of protein from crude nuclear extract. Leupeptin (0.3 g/ml), phenylmethylsulfonyl fluoride (5 mM), antipain (0.3 g/ml), and aprotinin (2 g/ml) were included in all nuclear extract buffers. Samples were incubated in the presence or absence of excess competitor oligonucleotides for 15 min at room temperature. Electrophoresis was performed at 30 mA at 4ЊC in a 0.5ϫ Tris borate-EDTA-5% polyacrylamide gel. For the supershift EMSA, the binding-reaction mixture was incubated with antibody for 30 min at 4ЊC, labeled oligonucleotide was added, and the mixture was incubated for 15 min at room temperature. Antibodies specific to the following proteins were obtained from Santa Cruz Biotechnology for use in supershift EMSA: ATF-1/CREB (recognizes all CREB/ATF family proteins), ATF-1/ATF-2, ATF-2, ATF-3, CREB-1 (CREB), CREB-2, CREM-1, PEA3, c-jun, egr-1, ets1/ets2, and c-fos. An antibody specific for the phosphorylated serine 133 form of CREB was obtained from Upstate Biotechnology Inc. CREB interactions were studied by addition of purified truncated CREB (CREB bZIP 254-327 [Santa Cruz Biotechnology]) to the binding-reaction mixture prior to the addition of labeled oligonucleotide.
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UV cross-linking and SDS-polyacrylamide gel electrophoresis. EMSA was performed as described above. UV cross-linking was performed as described previously (11) with a short-wavelength UV light box at 4ЊC for 60 min. An autoradiograph of the wet gel was used to locate the EMSA complexes. Regions of the gel containing the complexes were cut out, and the individual complexes were eluted at room temperature overnight in 50 mM Tris-HCl (pH 7.9)-0.1% sodium dodecyl sulfate (SDS)-0.1 mM EDTA-5 mM dithiothreitol-150 mM NaCl-0.1 mg of bovine serum albumin per ml. The eluted protein was precipitated with 4 volumes of acetone, washed with ethanol, and dried. It was then resuspended in Laemmli loading buffer, and SDS-polyacrylamide gel electrophoresis was performed. The 32 P-labeled proteins were visualized by autoradiography.
Methylation interference. The 5Ј-end-labeled oligonucleotide (either WtDRE or bCREO) was labeled with T4 kinase and methylated with 0.5% dimethyl sulfate for 2 min at room temperature. The sequence of WtDRE is shown in Table 1 , and the sequence of bCREO was GAACCGTGTGACACGA. These oligonucleotides were used in EMSA as described above. The complexes were transferred to DEAE membrane, the membrane was exposed to film to locate the complexes, and regions containing the bound and free probes were excised. The DNA was eluted and cleaved with piperidine, and equal counts of bound and free samples were resolved in a 15% acrylamide sequencing gel. S1 nuclease protection assay. BAL-17 cells were cultured in the presence of medium, 60 ng of PMA per ml, or 4 g of anti-IgM per ml for 18 h at 37ЊC prior to isolation of RNA by the guanidine thiocyanate method (12) . The murine bcl-2 probe (41) and a 1.8-kb BamHI-HindIII genomic fragment of ␤ 2 -microglobulin end labeled at the EcoRI site of exon 2 (43) were hybridized with 10 g of total RNA for 16 h at 55ЊC. Digestion with 200 U of S1 nuclease was performed for 1 h at 37ЊC. The protected fragments were separated on a 6% sequencing gel.
DNA fragmentation analysis. Ramos cells (5 ϫ 10 6 ) were cultured for 18 h in medium with no addition or the addition of 1 g of ionomycin per ml, 50 ng of PMA per ml, or both ionomycin and PMA. The cells were washed, centrifuged, and resuspended in 20 l of 10 mM EDTA-50 mM Tris-HCl-0.5% sodium N-lauroyl sarcosinate-0.5 g of protease K per ml and incubated for 1 h at 50ЊC. The samples were incubated for 1 h at 37ЊC after addition of 10 l of RNase A (100 g/ml) and then incubated for 5 min at 70ЊC. The samples were mixed with 10 l of 10 mM EDTA plus 1% low-melting-point agarose and electrophoresed in 40 mM Tris-acetate-1 mM EDTA in a 1.2% agarose gel.
RESULTS
Identification of two positive regulatory regions in the bcl-2 promoter. The bcl-2 major transcriptional promoter, P1, is located between bp Ϫ1390 and Ϫ1440 upstream from the translation start site (50) . bcl-2 sequence from Ϫ3934 to Ϫ1287 that contains the P1 promoter was inserted upstream of a promoterless luciferase reporter gene construct (Fig. 1A) , and reporter gene activity in DHL-9 cells (a human mature B-cell line) was assessed. We were unable to demonstrate any transcript initiation at the P2 promoter (8) . Constructs that contained both the P1 and P2 promoters yielded similar results, although the activity of the constructs with the P2 promoter was much lower because of the negative regulatory element just upstream of P2 (data not shown) (61) . Progressive 5Ј truncations of the bcl-2 sequence revealed a positive regulatory region between the SacII site at Ϫ1640 and a BsrFI site at Ϫ1526 (Fig. 1A) . In DHL-9 cells, this area resulted in a 3.8-fold increase in reporter gene activity over the basal promoter (Ϫ1526) construct. This appeared to be the only positive regulatory region. Similar results were obtained with the pre-Bcell line, Nall-1 (data not shown). Comparison of the murine and human bcl-2 sequences revealed a high degree of homology in this area.
To study the activity observed between SacII (Ϫ1640) and BsrFI (Ϫ1526) in more detail, subfragments of this area were inserted upstream of the BsrFI (Ϫ1526) site. Progressive 5Ј truncations within this area revealed two positive regulatory regions in DHL-9 cells (Fig. 1B) . The DRE, located between Ϫ1552 and Ϫ1526, was responsible for a 1.5-fold increase in basal promoter activity over that obtained with a P1 promoter control construct. This activity was preserved when a 3Ј deletion narrowed this element to Ϫ1552 through Ϫ1534.
The remainder of the positive regulatory activity was located between Ϫ1611 and Ϫ1552; this area is the URE. Preliminary studies suggest that the 5Ј end of the URE was located between Ϫ1611 and Ϫ1591. Constructs with deletions or additions of sequence between the two regions that disrupted the helical spacing resulted in promoter activities similar to that of the DRE alone (data not shown). These results suggest that disruption of the helical spacing between the URE and DRE leads to loss of the positive interaction between these elements. The URE has not been further characterized.
Sequence specificity of protein binding to the DRE. EMSA of nuclear extracts obtained from the B-cell lines DHL-9, Ramos, Nalm-6, and Reh with an oligonucleotide corresponding to bcl-2 sequence Ϫ1552 to Ϫ1525 or Ϫ1552 to Ϫ1535, both of which contain WtDRE, revealed four specific bands (the results for DHL-9 are shown in Fig. 2 ). Sequence mutation analysis within the DRE identified two distinguishable protein-binding sites by EMSA ( Fig. 2A ) and by EMSA with competition with the mutated oligonucleotides (Fig. 2B) . The results are summarized in Table 1 . The 5Ј site spanned the sequence from Ϫ1552 to Ϫ1541 and produced a single band on EMSA which corresponded to the fastest migrating of the four specific bands (Fig. 2, lane 5) . The 3Ј site spanned from Ϫ1547 to Ϫ1534 and produced one slowly migrating band and two more rapidly migrating bands (bands 1, 2, and 3 from most slowly to most rapidly migrating in Fig. 2 ). The 3Ј site contains a complete CRE consensus sequence, while the 5Ј site contains only part of the CRE. Consequently, they are referred to as the bcl-2 CRE (bCRE) site and the CRE-overlapping site (CREO site), respectively. EMSA with the CRE consensus oligonucleotide with bcl-2-flanking sequences yielded the same four complexes that were seen with the WtDRE oligonucleotide, and the two oligonucleotides competed against one another (data not shown). The CREO site does not appear to be homologous to any known transcription factor consensus-binding site. Transient-transfection assays were performed with DHL-9 cells and reporter gene constructs that contained mutations in the CREO and bCRE sites in the absence of the URE site. As seen in Table 1 , it appeared the bCRE site was responsible for most if not all of the positive regulatory activity in this area. The CREO site appeared to have only weak stimulatory activity. The 5Ј-and 3Ј-binding sites were also distinguishable by in vitro methylation interference (footprinting) analysis, which confirmed the site lengths of Ϫ1552 to Ϫ1541 and Ϫ1547 to Ϫ1534, respectively (Fig. 3) . Protein binding to the bCRE was strongly inhibited (Ͼ60% inhibition) by guanine methylation at sites Ϫ1545, Ϫ1543, Ϫ1541, and Ϫ1540. Weaker inhibition (35 to 60% inhibition) was seen at sites Ϫ1547 and Ϫ1535. Protein binding to the CREO site was strongly inhibited by methylation at sites Ϫ1549, Ϫ1548, Ϫ1547, and Ϫ1545. Weaker inhibition was seen at sites Ϫ1552 and Ϫ1543. This analysis confirmed an overlap between the bCRE and the CREO sites.
Characterization of the bCRE-binding proteins. To further study the proteins interacting with the bCRE site, UV crosslinking and SDS-polyacrylamide gel electrophoresis of the three upper bands obtained by EMSA with the mC1,4 oligo- nucleotide were performed (Fig. 4A) . The fourth band obtained with this probe corresponded to the CREO site complex and was not studied. UV cross-linking of the most slowly migrating bCRE band, band 1, obtained by EMSA with mC1,4 yielded two protein-DNA complexes migrating at 77 and 88 kDa (Fig. 4A, lane 3) . Correcting for oligonucleotide size, proteins of approximately 63 and 67 kDa were predicted. In addition, this EMSA band yielded two faintly labeled protein-DNA complexes migrating at 130 and 170 kDa, which may represent dimeric forms of the faster-migrating proteins.
UV cross-linking of bCRE band 2 revealed a protein-DNA complex of 53 kDa (corrected protein size, 43 kDa) (Fig. 4A,  lane 2) . A faintly labeled protein-DNA complex of approximately 100 kDa, which may represent a homodimeric complex of the 43-kDa protein, was seen. The fastest migrating bCRE band, band 3, yielded two protein-DNA complexes of 45 and 53 kDa (corrected protein sizes, 34 and 43 kDa, respectively) (lane 1). Again, a faintly labeled protein-DNA complex of approximately 94 kDa was seen, which may represent a heterodimeric complex.
EMSA supershift analyses of the bCRE complexes were performed with antibodies directed against several known CREBs (ATF-1, ATF-2, ATF-3, CREB, CREB-2, and CREM-1) and several non-CREBs (PEA3, c-jun/AP-1, c-fos, egr-1, and ets1/ets2). Performing this analysis with the mC1,4 oligonucleotide probe demonstrated a supershift of bCRE band 1 with antibodies against ATF-2 and ATF-1/ATF-2. bCRE band 2 was supershifted with antibodies against CREB and ATF-1/CREB, and bCRE band 3 was supershifted only with antibody against ATF-1/CREB (Fig. 4B) . None of the other antibodies tested shifted either the bCRE bands or the CREO band.
Western blot (immunoblot) analysis of DHL-9 nuclear extract revealed abundant expression of ATF-2 (reactive antigens found at 62, 67, and 170 kDa) and CREB (reactive antigen found at 43 kDa [data not shown]). By Western blot analysis, the ATF-1/ATF-2 antibody displayed weak cross-reactivity with the ATF-2 antigens, suggesting that the supershift Members of the CREB/ATF family form homo-and heterodimers. To further confirm the involvement of CREB/ATF family members in the bCRE complexes, EMSA of the mC1,4 oligonucleotide was performed in the presence of decreasing amounts of a truncated CREB that contains the DNA-binding and dimerization domains (Fig. 5) . High concentrations of this protein (Ͼ10 ng/l) effectively blocked the binding of nuclear extract proteins to both the bCRE and CREO sites, confirming that these sites overlap and that the bCRE site can function as a CRE site (data not shown). Lower concentrations (0.008 to 5 ng/l) of the truncated CREB produced one intermediate migrating band with concurrent relative diminution in the intensity of bCRE band 2 and 3 but not in the intensity of bCRE band 1 or of the CREO band (Fig. 5) . These results confirmed that the proteins involved in bCRE bands 2 and 3 are capable of dimerization with CREB. As ATF-2 is a distant relative of CREB and has not been shown to dimerize with CREB, it is not surprising that no interaction between the truncated CREB and the bCRE band 1 was seen (36) .
Thus, the bcl-2 CRE site appears to be able to form three complexes with B-cell nuclear extracts, each represented by a specific EMSA band. The most slowly migrating complex (bCRE band 1) appears to consist of dimerized 63-and 67-kDa forms of ATF-2. The middle complex (bCRE band 2) is apparently a homodimer of CREB, and the fastest-migrating complex (bCRE band 3) is a heterodimer of CREB and possibly ATF-1.
To confirm the importance of the CRE site in the full-length bcl-2 promoter, site-directed mutagenesis was used to create a 2-bp change in the CRE site in the WtURE/DRE construct (MutCRE). As shown in Fig. 6 , the promoter activity decreased by 83% relative to the WtURE/DRE construct.
Induction of bcl-2 promoter activity during B-cell activation and rescue from apoptosis. Because the CRE is an inducible regulatory element, we wished to determine whether a CREB was involved in the increase in bcl-2 expression during B-cell activation. DHL-9 cells could not be used for these studies because they do not express surface IgM. The murine B-cell line, BAL-17, was chosen because it has been shown to recapitulate many of the characteristics of primary B cells after surface Ig receptor cross-linking. Although BAL-17 cells express relatively high levels of bcl-2, cross-linking of the surface Ig receptor or treatment with PMA leads to a further 2.5-to 3.5-fold increase in bcl-2 mRNA levels (Fig. 7B, lanes 2 and 3) . To determine the effect on bcl-2 promoter activity, cross-linking of surface Ig receptor was performed with goat anti-IgM antibodies 24 h after transfection of the bcl-2-luciferase constructs. The bcl-2 promoter constructs used are shown in Fig.  7A . The activity of the bcl-2 promoter increased by threefold (Fig. 7C) .
We used either dibutyryl-cAMP or forskolin to increase cAMP levels. This PKA pathway is involved in the phosphorylation of CREBs in many different cell types. As shown in Fig.  7C , forskolin did not produce an increase in bcl-2 promoter activity. Similar negative results were obtained with dibutyrylcAMP (data not shown). Because CREB is phosphorylated by other kinases, including PKC, we treated the BAL-17 cells with PMA. PMA produced a threefold activation (Fig. 7C) . The increase in activity due to PMA was very similar to that observed with surface Ig receptor cross-linking. Simultaneous stimulation with PMA and Ig cross-linking resulted in little additional stimulation of promoter activity, suggesting that the stimulation evoked by surface Ig cross-linking was almost entirely due to a PKC mechanism. Similar results were obtained with a control plasmid (BglII CAT) that contains the somatostatin gene promoter CRE site. Treatment of BAL-17 cells with PMA led to a threefold increase in CAT activity, while treatment with forskolin had no effect (data not shown). The reason for the failure of increased cAMP levels to activate a CRE site in these cells is unclear. It is possible that an inhibitor of PKA is present in the cell lines we used for these studies.
The increase in activity of the bcl-2 promoter with both anti-IgM and PMA was dependent on the presence of the CRE site. As shown in Fig. 7C , there was no change in the activity of either the WtURE or MutCRE constructs. A promoter construct with the URE deleted showed only a 60% increase in activity with PMA. These results suggest that the bCRE site is required for the increased promoter activity and that interaction of the URE and bCRE results in maximal stimulation of promoter activity. Thus, bcl-2 expression is activated by surface Ig receptor cross-linking or by PMA through the CRE site in the 5Ј-flanking sequence. FIG. 5 . Interaction of a purified truncated CREB with the CREBs in DHL-9 nuclear extract by EMSA with the mC1,4 oligonucleotide. Decreasing amounts of a purified truncated CREB were added to a constant protein concentration from DHL-9 nuclear extract (2 g/l). The arrows indicate the complexes formed with DHL-9 nuclear extract, the complex formed by the truncated CREB protein, and the complex of intermediate mobility formed with the truncated CREB and with CREB in DHL-9 nuclear extract. Quantitation of the bands was performed for the EMSA with 1.0 and 5.0 ng of truncated CREB per ml. There was no change in the relative intensity of the bCRE1 and CREO bands. With 1.0 and 5.0 ng of truncated CREB per l, bCRE band 2 decreased by 18 and 70%, respectively, and bCRE band 3 decreased by 28 and 83%, respectively. VOL. 16, 1996 INDUCTION OF bcl-2 BY CREB PROTEINS 5551
To confirm that CREB was phosphorylated by both surface Ig receptor cross-linking and PMA, we performed EMSA with an antibody specific for phosphorylated CREB. Figure 7D demonstrates that very little phosphorylated CREB is present in unstimulated BAL-17 cells. Treatment with either anti-IgM or PMA led to the appearance of a complex that was supershifted with the antibody specific for phosphorylated CREB (Fig. 7D, lanes 4 and 6) . Thus, phosphorylation of CREB after surface Ig cross-linking is mediated by PKC and the phosphorylated CREBs activate the bcl-2 promoter.
BAL-17 cells express relatively high levels of bcl-2, so we wished to examine the up-regulation of bcl-2 in a mature B-cell line that expressed low levels of bcl-2. We treated the DHL-9 cell line with PMA for 18 h after transfection of the bcl-2-luciferase constructs. The activity of the bcl-2 promoter increased by ninefold, and the increase was dependent on the CRE site (Fig. 8A) . As was the case for BAL-17 cells, maximal stimulation required the presence of the URE. Analysis of the CREBs in DHL-9 nuclear extracts revealed that phosphorylation on serine 133 occurred after treatment of the cells with PMA and to a lesser extent after treatment with forskolin (Fig.  8B, lanes 4 and 6) . As was the case with BAL-17 cells, treatment of DHL-9 cells with forskolin did not result in an increase in bcl-2 promoter activity (data not shown).
To further demonstrate the importance of CREB in the regulation of the bcl-2 promoter, cotransfection experiments were performed with a wild-type CREB expression vector or a dominant negative CREB M1 expression vector. The dominant negative CREB contains an alanine at position 133 and cannot be phosphorylated (21, 51) . As shown in Fig. 8C , cotransfection with either the wild-type CREB or CREB M1 resulted in a twofold increase in the constitutive activity of the bcl-2 promoter. With PMA stimulation, there was a slight increase in promoter activity with the wild-type CREB construct and a dramatic decrease with the CREB M1 construct. These changes were mediated through the bcl-2 CRE site, because there was no change in the activity of the promoter construct with mutated CRE site (Fig. 8C) . Furthermore, a construct with two CRE sites linked to the simian virus 40 promoter showed changes similar to the bcl-2 promoter when wild-type and mutant CREB expression vectors were cotransfected (Fig. 8D) . The CRE site was required since a construct with two 1-binding sites showed no change in activity with cotransfection of either wild-type or M1 CREB (Fig. 8D) . These results provide additional support for the role of phosphorylated CREBs in the regulation of the bcl-2 promoter during B-cell activation.
We also wished to determine whether the CRE site in the bcl-2 promoter mediated the increase in bcl-2 mRNA that is seen in more immature B-cell lines that are rescued from apoptosis induced by anti-IgM or calcium ionophores. Treatment with phorbol esters prevents the apoptosis. We used the Epstein-Barr virus-negative Ramos cell line to avoid the confounding effects of Epstein-Barr virus gene products on bcl-2 expression. We confirmed by several different techniques including cell survival and DNA fragmentation analysis that ionomycin caused apoptosis in Ramos cells (Fig. 9A and B) . Treatment with PMA protected the cells from apoptosis ( Fig.  9A and B) . Ramos cells were transfected with the bcl-2 promoter-luciferase constructs and treated with ionomycin, PMA, or ionomycin plus PMA for 6 h before being harvested. As shown in Fig. 9C , treatment with PMA or PMA plus ionomycin resulted in a 12-fold increase in bcl-2 promoter activity. There was no increase in promoter activity if the CRE site was mutated. Finally, we demonstrated that treatment of Ramos cells with PMA resulted in phosphorylation of CREBs at serine 133 and that treatment with forskolin had a smaller effect (Fig. 9D,  lanes 4 and 5) .
DISCUSSION
We have identified the major positive regulatory region of the bcl-2 promoter in B cells and demonstrated that a CRE site mediates both basal expression and induction of the bcl-2 promoter region in B cells following activation of PKC. CREBs have been shown to mediate both constitutive and kinaseinducible gene expression (29, 44, 58) . Although negative regulatory elements have been described (8, 61) , this is the first VOL. 16, 1996 INDUCTION OF bcl-2 BY CREB PROTEINS 5553 report of a positive regulatory element in the bcl-2 promoter. The constitutive positive region is active in both pre-B and mature B cells. We have previously demonstrated that the bcl-2 promoter is repressed in pre-B cells by 1-binding factors and that expression of bcl-2 is low in pre-B cells (8) . We describe two discrete positive regulatory regions, referred to as the URE and the DRE. Our preliminary results demonstrate that deletions or additions of sequence between the two sites that disrupt the helical spacing lead to loss of activity. Although we have not completed the characterization of the URE or identified the transcription factor that binds to the URE, it is possible that protein-protein interactions between CREB and the URE factor are important. There are many examples of interactions between two regulatory elements that can be destroyed by a change in helical spacing (27, 46, 49, 55) . In addition, the CREB interacts with factors that bind to an adjacent AP-1 site in a manner dependent on helical spacing (24) .
The results of in vitro methylation analysis revealed that the bcl-2 DRE consisted of two overlapping sites, CREO and bCRE. Transient-transfection analysis revealed that the bCRE site was associated with most of the activity in this region. EMSA with transcription factor antibodies, UV cross-linking followed by SDS polyacrylamide gel electrophoresis, and heterodimerization with a truncated CREB were performed to demonstrate that CREB family members bind to the bCRE site in vitro.
The presence of a CRE site in the bcl-2 promoter implies that the regulation of bcl-2 expression is linked to a signal transduction pathway in B cells. bcl-2 induction is seen in primary B cells with activation and presumably protects the cells from apoptosis. It has been demonstrated that CREB can be phosphorylated and transcriptionally activated by PKC (59) . PKC phosphorylates CREB in B cells (57) . This is of interest because it may represent another pathway involved in the activation of B cells. Cross-linking of surface Ig results in transactivation of a CRE-dependent promoter-CAT construct (56) . Agents that increase cAMP levels did not activate the CRE-dependent promoter but could act synergistically with cross-linking of surface Ig.
We have shown that cross-linking of surface Ig receptor on mature B cells leads to increased bcl-2 promoter activity through a PKC-dependent pathway involving phosphorylation of CREB. This pathway may provide a mechanism for selection of long-lived antigen-reactive B cells by coupling antigen recognition to protection from apoptosis. Reagents that in- crease cAMP levels have no effect on the activity of the DRE, either alone or in combination with PMA or anti-IgM. BAL-17 cells are derived from a malignant lymphoma and resemble partially activated mature B cells. They express relatively high levels of bcl-2 constitutively. It is possible that the magnitude of induction of the bcl-2 promoter would be greater in B cells that express lower levels of bcl-2 such as resting, mature B cells. In support of this, we find that the magnitude of induction of bcl-2 expression after phorbol ester treatment of another mature B-cell line, DHL-9, is approximately threefold greater than that seen in BAL-17 cells. A dominant negative CREB construct interferes with the PMA-induced activation of the bcl-2 promoter. Cotransfection of a wild-type CREB construct increased the constitutive activity by twofold. Stimulation with PMA resulted in a similar increase in activity of the bcl-2 promoter whether wild-type CREB was cotransfected or not. Since we find that 10 to 20% of the CREBs present in DHL-9 cells are phosphorylated in response to PMA (Fig. 8B and Western blotting data [not shown]), the increase in the level of unphosphorylated CREB may not result in more active phosphorylated CREB. Therefore, no increase in promoter activity with PMA would be observed. The dominant negative CREB appears to interfere with the function of the phosphorylated CREB, perhaps by forming inactive heterodimers.
We have demonstrated that a similar signal transduction pathway is involved in the up-regulation of bcl-2 expression in immature B cells given a survival signal. Treatment of Ramos cells with phorbol esters prevents apoptosis induced by ionomycin or by surface IgM cross-linking. bcl-2 mRNA is upregulated, and we show that expression of the bcl-2 promoter increases by 12-fold following phorbol ester treatment. This increase in expression is dependent on the CRE site in the bcl-2 promoter. CREBs in phorbol ester-treated Ramos cells are phosphorylated by a pathway involving PKC. These results are similar to those found in mature B cell lines and provide a demonstration of the physiological significance of signals through the bcl-2 promoter CRE site.
We have shown that the CRE site mediates the PKC-dependent increase in bcl-2 levels in B cells at two different stages of development. It will be interesting to determine whether the CRE site plays a role in bcl-2 induction in other cells in which Bcl-2 prevents apoptosis, including myeloid, breast, neural, and T cells. Recent data have demonstrated that phosphorylation of CREBs during T-cell activation occurs in a cAMPindependent manner and that the phosphorylation of CREB is inhibited by rapamycin in T cells (15) . In addition, bcl-2 expression is inhibited by rapamycin (38) . Our description of CRE site regulation of the bcl-2 promoter suggests that the inhibitory effect of rapamycin on bcl-2 expression may be due to its interference with CREB phosphorylation in T cells. Similarly, in a myeloid cell line that can be rescued from apoptosis by interleukin-3, the interleukin-3 receptor modulates bcl-2 mRNA through a PKC-dependent pathway (47) . Our results raise the possibility that the PKC-CREB pathway we have identified is responsible for the induction of bcl-2 mRNA in these cells. It is intriguing to speculate that CREBs acting through the CRE site serve as a general mechanism for coupling surface receptor stimulation to protection from apoptosis by Bcl-2.
